NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The Netherlands.
A number of advances in cancer therapy during the last two years were reported, including new strategies, new targets and new compounds. New strategies were developed in gene therapy, drug delivery, drug targeting and prodrug design. New targets within the broad family of kinases, histone deacetylases, proteasomes and hypoxic factors were defined. Improved compounds including tubulin interacting agents, bioreductive agents, angiogenesis inhibitors, DNA interactive agents, anthracyclines, taxanes, cyclin- and tyrosine kinase inhibitors have recently reached the stage of clinical trials. Special attention has been given to chemoprevention and also to structure-activity relationships as a tool for speeding the development of better drugs. The aim of the meeting was to present and discuss the recent results in this area with respect to the R and D of new generations of anticancer compounds. This review focuses on a number of the most recent advances in the area of strategies and anticancer drug and prodrug design presented and discussed in plenary and poster sessions.
Niculescu-Duvaz
I
I
2 Radcliffe Gardens, Carshalton, Surrey, SM5 4PF, UK. ion@icr.ac.uk